Moreover, we discovered interactions between the lncRNA NCALD and ERα regions, which suggested that in the future, we can develop inhibitors targeting lncRNA NCALD fragment, which destroy its scaffold effect and prevent ERα from binding to GRHL2 promoter region, and thus inhibit the expression of GRHL2 to provide a new therapy for luminal breast cancer. Here, ESR1 is linked to breast carcinoma.